The“gold standard”for more than half a century: compound levodopa in the treatment of Parkinson′s disease
10.3760/cma.j.cn113694-20240321-00176
- VernacularTitle:半个多世纪的“金标准”：复方左旋多巴治疗帕金森病
- Author:
Qin XIAO
1
;
Haibo CHEN
;
Chunfeng LIU
Author Information
1. 上海交通大学医学院附属瑞金医院神经内科 上海交通大学医学院附属瑞金医院神经病学研究所，上海 200025
- Keywords:
Parkinson disease;
Compound levodopa;
Drug reference
- From:
Chinese Journal of Neurology
2024;57(11):1169-1176
- CountryChina
- Language:Chinese
-
Abstract:
Today, medication remains a fundamental guarantee of long-term improvement in the quality of life for patients with Parkinson′s disease (PD). Since the 1960s, compound levodopa has been used to treat PD, and has been proved to be the most effective drug for the treatment of PD, which can not only improve the motor symptoms of PD patients, but also improve the quality of life. However, there are still some misunderstandings about the use of compound levodopa in clinical practice. With the progression of the disease, the related motor complications caused by its treatment have caused certain troubles to both clinicians and patients. This paper reviewed the results of related clinical studies at home and abroad, as well as guidelines and consensus, and carried out a comprehensive and systematic analysis and summary of the pharmacological characteristics of compound levodopa, evidence-based research evidence, clinical standard use, etc, combined with China′s national conditions and clinical practice, hoping to standardize the reasonable clinical application of compound levodopa and provide drug reference for the majority of clinical workers.
